9 News. A new treatment (Venetoclax + Azacitidine) appears to be more aggressive than the cancer it treats.
9 News. For the second year in a row, UCHealth is doing their "Hit the Mitt" campaign - if a player hits a banner in the stands of Coors Field with a home run, UCHealth donates $5,000 to a leukemia and lymphoma society.
Colorado Public Radio covers a CU trial drug, venetoclax, which is producing a 91 percent response rate in Acute Myeloid Leukemia (AML).
Chemotherapy and bone marrow transplant are the standard-of-care for AML. Now the basic science from Jordan’s lab and the results from clinical trials in Pollyea’s and Smith’s patients are leading to a new paradigm for the treatment of AML.